Veristat rolled out InStat, a fully automated biostatistics platform positioned to compress clinical trial data readouts from weeks to days. The company said sponsors can receive submission-ready tables, listings, and figures in five days or less using validated statistical engines plus expert biostatistician review. The platform translates sponsor biostatistical descriptions into precise specifications and supports collaboration through a secure portal. Veristat said its first sponsor use case, Clene Nanomedicine, applied InStat to NfL biomarker analyses as part of its Subpart H accelerated approval pathway planning. If adoption broadens, InStat could shift how CROs and sponsors allocate biostatistics resources and may reduce delays between data lock and regulatory submission package assembly.